Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company.
Trulieve Cannabis Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$32.42|
|52 Week High||CA$27.37|
|52 Week Low||CA$67.45|
|1 Month Change||1.60%|
|3 Month Change||-25.30%|
|1 Year Change||13.16%|
|3 Year Change||90.71%|
|5 Year Change||n/a|
|Change since IPO||224.85%|
Recent News & Updates
Is Trulieve Cannabis (CSE:TRUL) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|TRUL||CA Pharmaceuticals||CA Market|
Return vs Industry: TRUL exceeded the Canadian Pharmaceuticals industry which returned 8.6% over the past year.
Return vs Market: TRUL underperformed the Canadian Market which returned 30.3% over the past year.
Stable Share Price: TRUL is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: TRUL's weekly volatility (7%) has been stable over the past year.
About the Company
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays.
Trulieve Cannabis Fundamentals Summary
|TRUL fundamental statistics|
Is TRUL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TRUL income statement (TTM)|
|Cost of Revenue||US$211.86m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 15, 2021
|Earnings per share (EPS)||0.50|
|Net Profit Margin||12.81%|
How did TRUL perform over the long term?See historical performance and comparison
Is Trulieve Cannabis undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TRUL (CA$32.42) is trading above our estimate of fair value (CA$8.91)
Significantly Below Fair Value: TRUL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TRUL is poor value based on its PE Ratio (52.2x) compared to the Canadian Pharmaceuticals industry average (19.2x).
PE vs Market: TRUL is poor value based on its PE Ratio (52.2x) compared to the Canadian market (13.6x).
Price to Earnings Growth Ratio
PEG Ratio: TRUL is poor value based on its PEG Ratio (2.8x)
Price to Book Ratio
PB vs Industry: TRUL is overvalued based on its PB Ratio (6.3x) compared to the CA Pharmaceuticals industry average (2.4x).
How is Trulieve Cannabis forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRUL's forecast earnings growth (18.7% per year) is above the savings rate (1.6%).
Earnings vs Market: TRUL's earnings (18.7% per year) are forecast to grow faster than the Canadian market (12% per year).
High Growth Earnings: TRUL's earnings are forecast to grow, but not significantly.
Revenue vs Market: TRUL's revenue (22.3% per year) is forecast to grow faster than the Canadian market (6.8% per year).
High Growth Revenue: TRUL's revenue (22.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRUL's Return on Equity is forecast to be high in 3 years time
How has Trulieve Cannabis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRUL has a high level of non-cash earnings.
Growing Profit Margin: TRUL's current net profit margins (12.8%) are higher than last year (6.4%).
Past Earnings Growth Analysis
Earnings Trend: TRUL's earnings have grown significantly by 33.9% per year over the past 5 years.
Accelerating Growth: TRUL's earnings growth over the past year (290.6%) exceeds its 5-year average (33.9% per year).
Earnings vs Industry: TRUL earnings growth over the past year (290.6%) exceeded the Pharmaceuticals industry 115.1%.
Return on Equity
High ROE: TRUL's Return on Equity (12.1%) is considered low.
How is Trulieve Cannabis's financial position?
Financial Position Analysis
Short Term Liabilities: TRUL's short term assets ($442.1M) exceed its short term liabilities ($76.7M).
Long Term Liabilities: TRUL's short term assets ($442.1M) exceed its long term liabilities ($313.3M).
Debt to Equity History and Analysis
Debt Level: TRUL's debt to equity ratio (30%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if TRUL's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: TRUL's debt is well covered by operating cash flow (31.4%).
Interest Coverage: TRUL's interest payments on its debt are well covered by EBIT (12x coverage).
What is Trulieve Cannabis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRUL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRUL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRUL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TRUL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kim Rivers (43 yo)
Ms. Kimberly Rivers, also known as Kim, has been Principal Executive Officer and Director at Harvest Health & Recreation Inc. since October 01, 2021. She has been the Chairman and President of Trulieve Can...
CEO Compensation Analysis
Compensation vs Market: Kim's total compensation ($USD1.06M) is below average for companies of similar size in the Canadian market ($USD2.89M).
Compensation vs Earnings: Kim's compensation has increased by more than 20% in the past year.
Experienced Management: TRUL's management team is considered experienced (2 years average tenure).
Experienced Board: TRUL's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TRUL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.4%.
Trulieve Cannabis Corp.'s employee growth, exchange listings and data sources
- Name: Trulieve Cannabis Corp.
- Ticker: TRUL
- Exchange: CNSX
- Founded: 1940
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$5.898b
- Shares outstanding: 181.93m
- Website: https://www.trulieve.com
Number of Employees
- Trulieve Cannabis Corp.
- 6749 Ben Bostic Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 23:30|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.